Product Code: TMRGL4067
The report provides revenue of the global substance abuse treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global substance abuse treatment market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the substance abuse treatment market.
The report delves into the competitive landscape of the global substance abuse treatment market. Key players operating in the global substance abuse treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global substance abuse treatment market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Substance Abuse Treatment Market
4. Market Overview
- 4.1. Introduction
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Substance Abuse Treatment Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Porter's Five Force Analysis
- 5.3. Value Chain Analysis
- 5.4. Key Industry Development
- 5.5. Top Company's Product Specification Details
6. Global Substance Abuse Treatment Market Analysis and Forecast, by Treatment Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Treatment Type, 2017-2031
- 6.3.1. Alcohol Addiction
- 6.3.1.1. Disulfiram
- 6.3.1.2. Acamprosate
- 6.3.1.3. Naltrexone
- 6.3.1.4. Others
- 6.3.2. Nicotine Addiction
- 6.3.2.1. Total NRT Therapy
- 6.3.2.2. Varenicline
- 6.3.2.3. Bupropion
- 6.3.3. Drug Abuse Treatment
- 6.3.3.1. Methadone
- 6.3.3.2. Buprenorphine
- 6.3.3.3. Naltexone
- 6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Substance Abuse Treatment Market Analysis and Forecast, by Distribution Channel Type
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies & Drug Stores
- 7.3.3. Others (online sales)
- 7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Substance Abuse Treatment Market Analysis and Forecast, by Region
- 8.1. Key Findings
- 8.2. Market Value Forecast, by Region
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
- 8.3. Market Attractiveness Analysis, by Region
9. North America Substance Abuse Treatment Market Analysis and Forecast
- 9.1. Introduction
- 9.2. Market Value Forecast, by Treatment Type, 2017-2031
- 9.2.1. Alcohol Addiction
- 9.2.1.1. Disulfiram
- 9.2.1.2. Acamprosate
- 9.2.1.3. Naltrexone
- 9.2.1.4. Others
- 9.2.2. Nicotine Addiction
- 9.2.2.1. Total NRT Therapy
- 9.2.2.2. Varenicline
- 9.2.2.3. Bupropion
- 9.2.3. Drug Abuse Treatment
- 9.2.3.1. Methadone
- 9.2.3.2. Buprenorphine
- 9.2.3.3. Naltexone
- 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies & Drug Stores
- 9.3.3. Others (online sales)
- 9.3.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.5. Hospital Pharmacies
- 9.3.6. Retail Pharmacies & Drug Stores
- 9.3.7. Others (online sales)
- 9.4. Market Value Forecast, by Country, 2017-2031
- 9.4.1. U.S.
- 9.4.2. Canada
- 9.5. Market Attractiveness Analysis
- 9.5.1. By Treatment Type
- 9.5.2. By Distribution Channel Type
- 9.5.3. By Country
10. Europe Substance Abuse Treatment Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Market Value Forecast, by Treatment Type, 2017-2031
- 10.2.1. Alcohol Addiction
- 10.2.1.1. Disulfiram
- 10.2.1.2. Acamprosate
- 10.2.1.3. Naltrexone
- 10.2.1.4. Others
- 10.2.2. Nicotine Addiction
- 10.2.2.1. Total NRT Therapy
- 10.2.2.2. Varenicline
- 10.2.2.3. Bupropion
- 10.2.3. Drug Abuse Treatment
- 10.2.3.1. Methadone
- 10.2.3.2. Buprenorphine
- 10.2.3.3. Naltexone
- 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies & Drug Stores
- 10.3.3. Others (online sales)
- 10.3.4. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.4.1. Germany
- 10.4.2. U.K.
- 10.4.3. France
- 10.4.4. Italy
- 10.4.5. Spain
- 10.4.6. Rest of Europe
- 10.5. Market Attractiveness Analysis
- 10.5.1. By Treatment Type
- 10.5.2. By Distribution Channel Type
- 10.5.3. By Country/Sub-region
11. Asia Pacific Substance Abuse Treatment Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Treatment Type, 2017-2031
- 11.2.1. Alcohol Addiction
- 11.2.1.1. Disulfiram
- 11.2.1.2. Acamprosate
- 11.2.1.3. Naltrexone
- 11.2.1.4. Others
- 11.2.2. Nicotine Addiction
- 11.2.2.1. Total NRT Therapy
- 11.2.2.2. Varenicline
- 11.2.2.3. Bupropion
- 11.2.3. Drug Abuse Treatment
- 11.2.3.1. Methadone
- 11.2.3.2. Buprenorphine
- 11.2.3.3. Naltexone
- 11.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies & Drug Stores
- 11.3.3. Others (online sales)
- 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.4.1. Japan
- 11.4.2. China
- 11.4.3. India
- 11.4.4. Australia & New Zealand
- 11.4.5. Rest of APAC
- 11.5. Market Attractiveness Analysis
- 11.5.1. By Treatment Type
- 11.5.2. By Distribution Channel Type
- 11.5.3. By Country/Sub-region
12. Latin America Substance Abuse Treatment Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Treatment Type, 2017-2031
- 12.2.1. Alcohol Addiction
- 12.2.1.1. Disulfiram
- 12.2.1.2. Acamprosate
- 12.2.1.3. Naltrexone
- 12.2.1.4. Others
- 12.2.2. Nicotine Addiction
- 12.2.2.1. Total NRT Therapy
- 12.2.2.2. Varenicline
- 12.2.2.3. Bupropion
- 12.2.3. Drug Abuse Treatment
- 12.2.3.1. Methadone
- 12.2.3.2. Buprenorphine
- 12.2.3.3. Naltexone
- 12.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.3.1. Hospital Pharmacies
- 12.3.2. Retail Pharmacies & Drug Stores
- 12.3.3. Others (online sales)
- 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.4.1. Brazil
- 12.4.2. Mexico
- 12.4.3. Rest of LATAM
- 12.5. Market Attractiveness Analysis
- 12.5.1. By Treatment Type
- 12.5.2. By Distribution Channel Type
- 12.5.3. By Country/Sub-region
13. Middle East & Africa Substance Abuse Treatment Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Treatment Type, 2017-2031
- 13.2.1. Alcohol Addiction
- 13.2.1.1. Disulfiram
- 13.2.1.2. Acamprosate
- 13.2.1.3. Naltrexone
- 13.2.1.4. Others
- 13.2.2. Nicotine Addiction
- 13.2.2.1. Total NRT Therapy
- 13.2.2.2. Varenicline
- 13.2.2.3. Bupropion
- 13.2.3. Drug Abuse Treatment
- 13.2.3.1. Methadone
- 13.2.3.2. Buprenorphine
- 13.2.3.3. Naltexone
- 13.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.3.1. Hospital Pharmacies
- 13.3.2. Retail Pharmacies & Drug Stores
- 13.3.3. Others (online sales)
- 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.4.1. GCC Countries
- 13.4.2. South Africa
- 13.4.3. Rest of MEA
- 13.5. Market Attractiveness Analysis
- 13.5.1. By Treatment Type
- 13.5.2. By Distribution Channel Type
- 13.5.3. By Country/Sub-region
14. Competitive Landscape
- 14.1. Market Player - Competition Matrix (by tier and size of companies)
- 14.2. Market Share Analysis, by Company, 2021
- 14.3. Company Profiles
- 14.3.1. Alkermes
- 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.1.2. Company Financials
- 14.3.1.3. Growth Strategies
- 14.3.1.4. SWOT Analysis
- 14.3.2. Allergan plc
- 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.2.2. Company Financials
- 14.3.2.3. Growth Strategies
- 14.3.2.4. SWOT Analysis
- 14.3.3. Indivior plc
- 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.3.2. Company Financials
- 14.3.3.3. Growth Strategies
- 14.3.3.4. SWOT Analysis
- 14.3.4. Noramco (part of SK Capital Partners)
- 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.4.2. Company Financials
- 14.3.4.3. Growth Strategies
- 14.3.4.4. SWOT Analysis
- 14.3.5. Teva Pharmaceutical Industries Ltd.
- 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.5.2. Company Financials
- 14.3.5.3. Growth Strategies
- 14.3.5.4. SWOT Analysis
- 14.3.6. Pfizer, Inc.
- 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.6.2. Company Financials
- 14.3.6.3. Growth Strategies
- 14.3.6.4. SWOT Analysis
- 14.3.7. GlaxoSmithKline plc
- 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.7.2. Company Financials
- 14.3.7.3. Growth Strategies
- 14.3.7.4. SWOT Analysis
- 14.3.8. Mallinckrodt plc
- 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.8.2. Company Financials
- 14.3.8.3. Growth Strategies
- 14.3.8.4. SWOT Analysis
- 14.3.9. BioCorRx, Inc.
- 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.9.2. Company Financials
- 14.3.9.3. Growth Strategies
- 14.3.9.4. SWOT Analysis
- 14.3.10. Glenmark Pharmaceuticals Ltd.
- 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 14.3.10.2. Company Financials
- 14.3.10.3. Growth Strategies
- 14.3.10.4. SWOT Analysis